News Snapshot:
The protein-based Covid-19 vaccine is engineered from the genetic sequence of the SARS-CoV-2 virus’ initial strain. Credit: Prasesh Shiwakoti (Lomash) on Unsplash. Novavax has obtained emergency use authorization (EUA) for its Covid-19 vaccine, Nuvaxovid (NVX-CoV2373), from the Taiwan Food and Drug Administration for use in people of the age 18 years and above. The protein-based vaccine is engineered from the genetic sequence of the SARS-CoV-2 virus’ initial strain. Developed utilising Novavax’s recombinant nanoparticle technology to generate antigen obtained from the coronavirus spike (S) protein, the vaccine is also formulated with the company’s saponin-based Matrix-M adjuvant. The totality of preclinical, manufacturing...
